Kraft Heinz to remove artificial dyes from U.S. products by end of 2027
Kraft Heinz said Tuesday that it will remove FD&C artificial dyes from its products by the end of 2027, and will not launch any new products in the U.S. containing those ingredients.
The company said in a release that about 10% of its U.S. items use FD&C colors, the synthetic additives that make many foods more visually appealing. Kraft Heinz brands that sell products with these dyes include Crystal Light, Kool-Aid, MiO, Jell-O and Jet-Puffed, according to a Kraft Heinz spokesperson.
The company removed artificial colors, preservatives and flavors from its Kraft macaroni and cheese in 2016 and its Heinz ketchup has never used artificial dyes, according to Pedro Navio, North America president at Kraft Heinz. It is unclear how removing the dyes will affect the company's business, as consumers could perceive the products as healthier but also may be less drawn to duller colors.
The decision follows pressure from the U.S. Food and Drug Administration and Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., for the food industry to pull back on artificial dyes as part of a larger so-called Make America Healthy Again platform.
The FDA in April announced a plan to phase out the use of petroleum-based synthetic dyes by the end of next year and replace them with natural alternatives. Besides the previously banned Red No. 3, other dyes that will be eliminated include red dye 40, yellow dye 5, yellow dye 6, blue dye 1, blue dye 2 and green dye 2, FDA Commissioner Marty Makary said at the time.
Kennedy said at the time that the FDA and the food industry have 'an understanding,' not a formal agreement, to remove artificial dyes. The Health and Human Services secretary discussed removing artificial food dyes during a meeting in March with top food executives from companies including Kraft Heinz, PepsiCo North America, General Mills, WK Kellogg, Tyson Foods, J.M. Smucker and the Consumer Brands Association, the industry's top trade group.
A spokesperson for Kraft Heinz said on Tuesday that the company looks forward to partnering with the administration 'to provide quality, affordable, and wholesome food for all.'
Momentum against food dyes had been building for years. In January, before President Donald Trump and Kennedy took office, the FDA announced a ban on the use of Red No. 3 dye in food and ingested drugs. The dye gives many candies and cereals their bright red color, but is also known to cause cancer in laboratory animals. The FDA allowed Red No. 3 to be used by food manufacturers for years, though the state of California had already banned the dye in 2023.
Kraft Heinz said in the release Tuesday that it has made more than 1,000 recipe changes over the past five years to improve product nutrition.
'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio,' Navio said. 'Above all, we are focused on providing nutritious, affordable and great-tasting food for Americans and this is a privilege we don't take lightly.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
a day ago
- Powys County Times
Rules for cattle relaxed in the new Bluetongue rules
Cattle moving from England into Wales WILL be permitted if they are vaccinated for bluetongue, the Welsh Government says - but sheep must still be tested before crossing the border. In a new announcement on Friday, the Welsh Government confirmed it will allow cattle fully vaccinated with Boehringer Ingelheim's Bultavo-3 vaccine, to move under licence, from a Restricted Zone to Wales without a pre-movement test – however this will not apply to sheep. There has been outrage amongst Powys farmers about rules being brought in from July 1 which would mean that any sheep that crossed the Welsh border would require a test for the bluetongue virus. Tests for Bluetongue cost anywhere from £40-£70 per animal meaning some farmers would be faced with bills of tens of thousands to move livestock across the border for grazing or for going to market. The Welsh Government confirmed that 'all sheep must be pre-movement tested and require an accompanying licence to move into Wales to live from the Restricted Zone (RZ) in England, as no vaccine products currently meet the requirements for protecting sheep from BTV-3 to allow them to move out of the RZ.' Deputy First Minister with responsibility for Climate Change and Rural Affairs, Huw Irranca-Davies, said: 'My goal at this stage remains to keep Bluetongue out of Wales for the benefit of our animals and those who keep them. 'The economic and farmer wellbeing concerns caused by dealing with severe Bluetongue are first and foremost in my mind. "I also want to allow more time to observe the severity of the disease in England, and for keepers to vaccinate their herds and flocks. Help support trusted local news Sign up for a digital subscription now: As a digital subscriber you will get Unlimited access to the Oswestry Advertizer website Advert-light access Reader rewards 'I have made clear the thinking behind my decision in the Senedd this week, but I want to keep it under review. Should the evidence change, and we need to alter the policy, we will revisit and review this in a dynamic way. 'Our shared priority over the coming weeks is to promote vaccine take-up. All representatives at the Roundtable I recently convened were unanimous in their support for vaccination as the best method of protecting livestock and reducing the impacts of Bluetongue." 'I cannot in all conscience invite Bluetongue into Wales, but we are prepared to adapt to the evolving disease situation.' In the announcement, the Welsh Government also confirmed that as a response to increased risk of Bluetongue, including 'temperatures that are consistent with the active transmission period,' these measures will come into force as of today (June 20) in relation to the current Restricted Zone in England, which covers the east of England.
The Independent
2 days ago
- The Independent
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need
US medicines regulator the Food and Drug Administration (FDA) has approved a groundbreaking HIV prevention jab hailed as having the potential to quell the Aids pandemic. But the moment has been overshadowed by the spectre of aid cuts, placing in doubt whether this breakthrough injection – lenacapavir – will get to the people who need it most. Lenacapavir given in a twice-yearly injection stops HIV from replicating, protecting close to 100 per cent of people from developing the virus if they are exposed to it. This approval is one of the last crucial steps to getting the drug, branded Yeztugo, out to patients. Although the FDA's approval only applies to US patients, the World Health Organization (WHO) said it paved the way for its own recommendation of the drug and for approval in other countries. Director of WHO's Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty described it as a 'regulatory milestone' adding: 'We are working with partners and national authorities to ensure lenacapavir reaches people who need it most – quickly, safely and equitably.' Researchers have raised concerns that, amid aid cuts, the jab will be too expensive to be taken up by lower-income countries. Gilead – the drugs company producing lencapavir – did not make public the cost of each dose to global funders but it announced a US price of $28,218 per year for each patient. 'If this game-changing medicine remains unaffordable, it will change nothing,' said Winnie Byanyima, executive director of the United Nations' Aids agency, UNAIDS. She called the approval of lenacapavir a 'breakthrough moment' adding the jab, 'could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit. ' UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218.' Dr Andrew Hill, a pharmacology research fellow at the University of Liverpool, worked on the research which found lenacapavir could be provided for as little as $25, including a 30 per cent profit margin. 'Scientifically, it's a great moment that we have a drug which has been judged to be safe and efficacious by a leading regulatory authority in the world,'' he said. 'Public health-wise and in terms of the epidemic, it's tragic because the drug is so expensive that it's not going to get used'. It is also unlikely to be affordable in the UK, he said, despite government promises to end new cases of HIV in England by 2030. A Gilead spokesperson said, 'Yeztugo is priced in line with existing branded PrEP [pre-exposure prophylaxis] options. We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage in the US. 'We're taking unprecedented actions with urgency to plan for access to lenacapavir for PrEP globally—particularly in low- and lower-middle-income countries where the need is greatest.' Gilead signed agreements with six pharmaceutical companies in India, Pakistan, Egypt, and the US to allow them to make generic versions of the drug in order to increase supply and drive down the cost of the jab. This will take some time. Gilead also agreed to sell enough doses of the jab to protect at least two million people over three years in lower-income countries. These would be paid for by global funders led by the US President's Emergency Plan for Aids Relief (Pepfar) and the Global Fund to Fight Aids, Tuberculosis and Malaria. However, The Independent reported earlier in the month that these doses are now at risk because of US funding cuts. A significant chunk of the money to fund the doses of lenacapavir was set to come from the US-led global Aids response programme, Pepfar, as well as the Global Fund whose biggest donor was the US. This funding is now uncertain. Figures previously reported by The Independent suggest President Trump's slashing of foreign aid has derailed the projected end of the Aids pandemic and could lead to four million extra deaths by 2030. 'It does feel like this thing that could help us end the epidemic sooner is suddenly receding in the chaos,' said Prof Linda-Gail Bekker, whose trial demonstrated lenacapavir's effectiveness. The aid-funded doses are thought to cost much less than the US list price of almost $30k but still roughly five times more expensive than Dr Hill believes is necessary. And they are in an initial pilot phase, he said: 'We need to get into a different level where we're giving lenacapavir to tens of millions of people'. This is even more important as aid cuts are slashing the HIV prevention budgets of governments across Africa, he said. 'We're in this crazy position where we have a brand new highly effective vaccine-like drug and actually we will probably see the epidemic get worse over the next four years.'
Medical News Today
2 days ago
- Medical News Today
Tretinoin for wrinkles: Uses, benefits, and more
Tretinoin is a prescription topical medication derived from vitamin A. It is clinically proven to reduce wrinkles and signs of aging. Tretinoin is a potent retinoid. Initially developed in the 1960s for acne treatment, tretinoin can also reduce the appearance of sun damage and wrinkles, and improve overall skin texture. Unlike cosmetic creams that only affect the skin's surface, tretinoin works at the cellular level to stimulate collagen production and accelerate skin renewal. However, tretinoin use requires careful consideration. The medication can cause initial skin irritation and increase sun sensitivity. It also demands consistent application over several months to achieve optimal results. Understanding how tretinoin works, its benefits and risks, and proper usage techniques is essential for anyone considering this treatment. YakobchukOlena/Getty Images Research shows tretinoin increases collagen production and improves skin thickness, elasticity, and overall appearance. The medication works particularly well for photodamage, including sun-induced wrinkles and age spots. Tretinoin is a prescription topical medication derived from vitamin A . It belongs to a class of compounds called retinoids, which are among the most studied aging support ingredients in dermatology. Healthcare professionals originally developed tretinoin to treat acne, but researchers later discovered its aging support properties. The Food and Drug Administration (FDA) has approved tretinoin specifically for treating photodamage and signs of aging. » Learn more about tretinoin. Tretinoin works through several mechanisms to reduce wrinkles: Increased cell turnover: Tretinoin accelerates the natural process of skin cell renewal, helping remove damaged surface cells and revealing newer, healthier skin underneath. Tretinoin accelerates the natural process of skin cell renewal, helping remove damaged surface cells and revealing newer, healthier skin underneath. Collagen stimulation: The medication triggers fibroblasts in the skin to produce more collagen, the protein responsible for skin structure and firmness. The medication triggers fibroblasts in the skin to produce more collagen, the protein responsible for skin structure and firmness. Improved blood flow: It enhances circulation in the skin, delivering more nutrients and oxygen to skin cells. It enhances circulation in the skin, delivering more nutrients and oxygen to skin cells. Normalized keratinization: It helps regulate how skin cells mature and shed, creating smoother, more even skin texture. Tretinoin offers several aging support benefits: reduces fine lines and wrinkles, particularly around the eyes and mouth improves skin texture and smoothness fades age spots and hyperpigmentation increases skin thickness and firmness enhances overall skin radiance and tone minimizes the appearance of enlarged pores prevents the formation of new wrinkles with continued use Research indicates that initial tretinoin benefits typically become visible after 4 weeks of regular application. skin irritation, discoloration, and peeling dryness and flaking burning or stinging sensation temporary worsening of skin appearance increase in sun sensitivity and higher risk of sunburn potential for severe skin irritation if overused unsafe during pregnancy or nursing may interact with other skin care products Most side effects diminish as the skin adjusts to treatment, typically within a few weeks. Individuals should consider several important factors before starting tretinoin: Medical consultation: A dermatologist should evaluate their skin type and determine the appropriate strength and formulation of tretinoin. Common strengths include 0.1%, 0.08%, and 0.04%. A dermatologist should evaluate their skin type and determine the appropriate strength and formulation of tretinoin. Common strengths include 0.1%, 0.08%, and 0.04%. Sun protection: Daily sunscreen use is essential, as tretinoin increases photosensitivity. Daily sunscreen use is essential, as tretinoin increases photosensitivity. Gradual introduction: Starting with lower concentrations and less frequent application helps minimize irritation. Starting with lower concentrations and less frequent application helps minimize irritation. Product interactions: Tretinoin may not combine well with certain skin care ingredients, including benzoyl peroxide, alpha hydroxy acids, and some vitamin C formulations. Tretinoin may not combine well with certain skin care ingredients, including benzoyl peroxide, alpha hydroxy acids, and some vitamin C formulations. Realistic expectations: Results require patience and consistent use over several months. People should always follow their healthcare professional's specific instructions, as they may differ from general guidelines based on individual skin type and treatment goals. However, these are general application principles to maximize benefits while minimizing side effects: Start slowly: Begin with application 2-3 times per week, gradually increasing frequency as skin tolerates treatment Evening application: Apply tretinoin at night, as it breaks down in sunlight Clean skin: Wash face with gentle cleanser and wait 15-20 minutes before applying tretinoin Small amount: Use a pea-sized amount for the entire face Gentle application: Spread evenly, avoiding the eye area and the corners of the nose and mouth Moisturize: Apply a gentle moisturizer 20-30 minutes after tretinoin application Tretinoin comes in several formulations : Creams: Most common form, available in concentrations from 0.025% to 0.1%. Creams work well for people with normal to dry skin. Most common form, available in concentrations from 0.025% to 0.1%. Creams work well for people with normal to dry skin. Gels: Better suited for oily or acne-prone skin. Available in similar concentration ranges as creams. Better suited for oily or acne-prone skin. Available in similar concentration ranges as creams. Solutions: Liquid formulations may cause more irritation, but penetrate the skin effectively. Liquid formulations may cause more irritation, but penetrate the skin effectively. Microsphere formulations: Newer delivery systems that release tretinoin slowly, potentially reducing irritation while maintaining effectiveness. Dermatologists typically start people on lower concentrations (0.025% or 0.05%) and may increase strength based on skin tolerance and response. Tretinoin is an effective prescription treatment for wrinkles and signs of aging. Clinical research shows it can reduce fine lines, improve skin texture, and stimulate collagen production. While tretinoin requires patience and careful use to avoid irritation, most people see significant improvements in skin appearance within several months of consistent use. Working with a dermatologist ensures proper selection of formulation and strength of tretinoin for wrinkles, while minimizing potential side effects.
